BASELINE ECHOCARDIOGRAPHIC PARAMETERS TO PREDICT CARDIOTOXICITY IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY

Breast cancer is often treated with anthracyclines and HER2 inhibitors, which are well-known cardiotoxic agents. Cancer therapeutics related cardiac dysfunction (CTRCD) has been defined by most guidelines using arbitrary left ventricular ejection fraction (LVEF) cut-off points or decreases. Our